Heartstream Breaks Some Hearts
Heartstream finally sold out to Hewlett-Packard at what observers believe was a disappointingly low price--below the IPO valuation. One problem: there weren't many available buyers for a company which has had trouble pioneering the brand new market for defibrillators that could be used by minimally trained personnel.
You may also be interested in...
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
The regulatory tools are for use in medical device development.
The US agency plans to hold a virtual workshop that will use breakout sessions to get stakeholder feedback on specific hurdles preventing more pediatric devices coming to market.